Clinton N. Corder

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 298 citations

Asthma, Rheumatology, Extension Trial +10

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni‐Berthold, Veronica J. Alexander, Qingqing Yang et al. · The Lancet Diabetes & Endocrinology · 2021 · 211 citations

Pharmacology, Pharmacotherapy, Medicine +1

Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies

Aaron I. Vinik, Michael Tuchman, Beth Safirstein et al. · Pain · 2006 · 163 citations

Pain Therapy, Lamotrigine 200, Lamotrigine 300 +15

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Gary T. Ferguson, J. Mark FitzGerald, Eugene R. Bleecker et al. · The Lancet Respiratory Medicine · 2017 · 121 citations

Asthma, Rheumatology, Allergy Medicine +7